[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556651":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":142,"collaborators":10,"id":144,"slug":10,"hasResults":145,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":145,"sex":151,"minAge":152,"maxAge":10,"enrollmentInfo":153,"targetDuration":10,"studyType":156,"phases":10,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All Participants cohort",null,"Participants with active LN who initiated belimumab as per local label alongside standard therapy\u002Fies under routine care conditions.",[13],"Other: None (Observational study)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"OTHER","None (Observational study)","Not Applicable since Observational Study",[9],[21],"Observational Study",[23],{"name":24,"affiliation":5,"role":25},"GSK Clinical Trials","STUDY_DIRECTOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"US GSK Clinical Trials Call Center","CONTACT","877-379-3718","GSKClinicalSupportHD@gsk.com",{"name":33,"role":29,"phone":34,"phoneExt":10,"email":31},"EU GSK Clinical Trials Call Center","+44 (0) 20 89904466",[36,57,71,85,99,113,128],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"GSK Investigational Site","RECRUITING","Baltimore","Maryland","21287","United States",{"type":44,"coordinates":45},"Point",[46,47],-76.61219,39.29038,{"lat":47,"lon":46},[50,51,54],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":52,"role":29,"phone":53,"phoneExt":10,"email":31},"EU GSK Clinical Trials Call Centre","+44 (0) 20 8990 4466",{"name":55,"role":56,"phone":10,"phoneExt":10,"email":10},"Michelle Petri","PRINCIPAL_INVESTIGATOR",{"facility":37,"status":38,"city":58,"state":59,"zip":60,"country":42,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Charlotte","North Carolina","28207",{"type":44,"coordinates":62},[63,64],-80.84313,35.22709,{"lat":64,"lon":63},[67,68,69],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":52,"role":29,"phone":53,"phoneExt":10,"email":31},{"name":70,"role":56,"phone":10,"phoneExt":10,"email":10},"Gordon Lam",{"facility":37,"status":38,"city":72,"state":73,"zip":74,"country":42,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Columbus","Ohio","43201",{"type":44,"coordinates":76},[77,78],-82.99879,39.96118,{"lat":78,"lon":77},[81,82,83],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":52,"role":29,"phone":53,"phoneExt":10,"email":31},{"name":84,"role":56,"phone":10,"phoneExt":10,"email":10},"Isabelle Ayoub",{"facility":37,"status":38,"city":86,"state":87,"zip":88,"country":42,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Hixson","Tennessee","37343-7908",{"type":44,"coordinates":90},[91,92],-85.23273,35.14063,{"lat":92,"lon":91},[95,96,97],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":52,"role":29,"phone":53,"phoneExt":10,"email":31},{"name":98,"role":56,"phone":10,"phoneExt":10,"email":10},"Joseph Huffstutter",{"facility":37,"status":38,"city":100,"state":10,"zip":101,"country":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Marseille","13005","France",{"type":44,"coordinates":104},[105,106],5.38107,43.29695,{"lat":106,"lon":105},[109,110,111],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":52,"role":29,"phone":53,"phoneExt":10,"email":31},{"name":112,"role":56,"phone":10,"phoneExt":10,"email":10},"Noemie Jourde Chiche",{"facility":37,"status":38,"city":114,"state":115,"zip":116,"country":117,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Rozzano","Milan","20089","Italy",{"type":44,"coordinates":119},[120,121],9.1559,45.38193,{"lat":121,"lon":120},[124,125,126],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":52,"role":29,"phone":53,"phoneExt":10,"email":31},{"name":127,"role":56,"phone":10,"phoneExt":10,"email":10},"Francesco Reggiani",{"facility":37,"status":38,"city":129,"state":10,"zip":130,"country":131,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Fukuoka","807-8556","Japan",{"type":44,"coordinates":133},[134,135],130.41667,33.6,{"lat":135,"lon":134},[138,139,140],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"name":52,"role":29,"phone":53,"phoneExt":10,"email":31},{"name":141,"role":56,"phone":10,"phoneExt":10,"email":10},"Shingo Nakayamada",{"type":143,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100556651",false,"NCT06527872","Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN","The Evaluation Of Use of Belimumab in Routine Care SEttings in Lupus Nephritis (LN): the OBSErve-LN Study","OBSErve-LN","Inclusion Criteria:\n\n* Participants to provide a signed informed consent at the time of enrollment per protocol,\n* Male or female aged 18 or over at initiation of belimumab,\n* Participants received belimumab in any formulation (subcutaneous or intravenous) for the treatment of active LN prescribed as per local label in combination with standard immunosuppressive therapy\u002Fies at initiation of belimumab,\n* Participants initiated belimumab 6 to 24 months prior to study enrollment,\n* Accessibility of medical records starting at belimumab initiation (including accessibility of medical records for the prior 12 months and confirmatory biopsy at any time prior to belimumab initiation),\n* Biopsy-confirmed LN diagnosis at any time prior to belimumab initiation for treatment of LN\n* Class III (focal LN) with or without Class V (membranous LN),\n* Class IV (diffuse LN) with or without Class V,\n* Class V.\n\nExclusion Criteria:\n\n* Participants receiving renal replacement therapy (i.e., dialysis, kidney transplant, or those in end-stage kidney disease) at initiation of belimumab,\n* Participant is concomitantly receiving another SLE targeted monoclonal antibody (MAb), or a MAb expected to compromise immune responses, at initiation of belimumab,\n* Participants in a clinical trial during the observation period (with the exception of allowing participation in other non-interventional studies),\n* Participant is pregnant at the initiation of belimumab,\n* Participant with a kidney transplant at the initiation of belimumab,\n* Participants will be excluded from the study if they are planning to become pregnant or are pregnant at study enrollment.","ALL","18 Years",{"count":154,"type":155},300,"ESTIMATED","OBSERVATIONAL","The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservation in belimumab treated participants.",[159],"Lupus Nephritis",[161,162,149,163,164],"Belimumab","Lupus nephritis","Renal function","Real world data","2026-07-01",{"date":167,"type":168},"2026-07-02","ACTUAL",{"date":170,"type":168},"2024-10-04",{"date":172,"type":155},"2029-03-29",{"name":5,"class":6},7]